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lox/lox conditional mouse model (eDll4 -/-), where Dll4 is specifically ablated on VE-Cadherin expressing cells. We investigated whether targeting Dll4 affected hematopoietic recovery following irradiation and BM recovery in a transplant setting. First, we show that the genetic ablation of Dll4 on VE-Cadherin + vessels in sublethally irradiated (300 rad) mice increased the BM and peripheral blood B (B220 + ) lymphoid content, but decreased their myeloid (CD11b + ) content. Interestingly, we observed the same changes in Blymphopoiesis and in myelopoiesis when the BM of eDll4 -/-was transplanted into lethally irradiated (800 rad) control mice but not when BM was transplanted from control to lethally irradiated eDll4 -/-mice. Together, we observed that Dll4 deletion on BM VE-Cadherin-primitive cells favours lymphoid commitment and differentiation. We are currently exploiting the mechanisms involved in this effect, such as the induction of "lymphoid-angiocrine" factors, among others. Several recent studies have provided new insights into the clonal and genetic architecture of human cancers, uncovering a wide clonal complexity and diversity of the cancer stem cells compartment. Our study was focused on Infant Acute Lymphoblastic Leukemia with MLL gene rearrangement (MLL+ infant ALL), a rare but aggressive disease occurring within 1 year of age. To unravel the dynamic of clonal evolution, we carried out a RQ-PCR clonal study and retrospective backtracking analysis in both paired diagnosis/relapse samples from infant patients, and in xenograft leukemias from serially transplanted NOD/SCID mice.
DYNAMIC COMPETITION OF MULTIPLE LEUKEMIA-INITIATING CLONES IN MLL+ INFANT ALL
We observed that multiple leukemic clones (identifiable with a unique Ig/TCR gene rearrangement) coexist within the tumor bulk already at the time of disease presentation. Each clone can potentially serve as L-IC and generate leukemia in mice, with a reversible clonal dominance. Clones which were dominant in the patient at diagnosis might either persist in mice or extinguish and disappear through serial passages in vivo. On the opposite, other clones which were indeed minor component of the leukemic bulk at diagnosis, might reactivate and take over in serially transplanted mice.
In conclusion our findings support a model of competition and selection of multiple pre-existing L-IC subclones, reversibly fluctuating between quiescence and expansion in a reversible fashion. This model might not only better reflect the biology of cancer pathogenesis and progression, but also help to understand the mechanisms leading to the drug resistance, occurrence of relapse and overall dismal prognosis in this high-risk leukemia.
SECRETED FRIZZLED-RELATED PROTEIN 2 REGULATES THE POOL OF HEMATOPOIETIC STEM CELLS
Franziska Bock, MSc, Christina Eckl, Dipl Biol, Rouzanna Istvanffy, Dr, Baiba Vilne, MSc, Sandra Grziwok, Christian Peschel, Prof Dr, Robert A.J. Oostendorp, PD, Dr Klinikum rechts der Isar, Technical University Munich, Munich, Germany
Recent gene expression analysis of hematopoietic stem cells (HSC) maintaining stromal cell lines point to a role of secreted frizzled-related protein 2 (Sfrp2) in the maintenance of HSC. We previously showed that the closely related Sfrp1 is required for HSC self-renewal. To study the role of Sfrp2, we compared hematopoiesis of wild-type (WT) mice (n=18) and Sfrp2 -/-littermates (n=17). We found that in steady-state hematopoiesis, mature blood cell subpopulations in peripheral blood, bone marrow, and spleen were unchanged. Earlier subpopulations in hematopoiesis [CD34 -, CD150 + , Lin -, Sca1 + , ckit + (LSK)] showed a decrease in cell number in Sfrp2 -/-mice. In addition, the number of colony forming cells (CFU-GM) was significantly increased in Sfrp2 -/-mice, suggesting that reduced Sfrp2 in the niche could result in an increased HSC proliferative activity. Transplantation experiments demonstrated that engraftment, especially B lymphocyte engraftment, was higher in peripherial blood, bone marrow, and spleen in Sfrp2 -/-recipients. These results suggest an increased proliferation in the Sfrp2-deficient environment. However, long-term follow-up of BrdU-pulsed mice showed no difference in BrdU retention in HSC in a WT or Sfrp2 mutant environment. Interestingly, in aged mice, we found a significant increase in CD34 -CD150 + LSK cells. As the BrdU retention results suggest that no cell cycle abnormalities occur, the latter data suggest that extrinsic Sfrp2-deficiency supports HSC survival. Our experiments show that Sfrp2 extrinsically regulates the HSC cell pool. This study should help our understanding of the multi-level mechanisms by which the niche regulates HSC. Throughout development, hemopoietic stem cells (HSC) migrate between and reside in specific microenvironments, where extrinsic interactions significantly influence their destiny. CD44 is a cell adhesive molecule, expressed on hemopoietic cells as well as in the extracellular matrix. Mice devoid of CD44 develop to a smaller size, but with normal mature blood cell lineage commitment. Our data demonstrates both fetal and adult steady state HSC (LSKCD150 + CD48 -cells) only expressed two-thirds the level of CD44 compared to more committed progenitors (LSKCD150 + CD48 + and LSKCD150 -cells). In addition, in the adult, CD44 is preferentially expressed by HSC in the endosteal region compared to their central counterparts and played a key role in the regulation of HSC proliferation in vitro and homing and spatial distribution in vivo. Furthermore, CD44 was critical in fetal hemopoietic cell migration from fetal liver (FL) to bone marrow (BM) and spleen. In addition to these roles, CD44 was also a negative regulator of HSC and progenitor pool, with age dependent changes to these pools in mice devoid of CD44. Importantly, neonatal bone marrow HSC devoid of CD44 had equivalent numbers of long-term reconstituting cells as their WT counterparts (1:17), but significantly higher long-term engraftment potential in a competitive limiting dilution transplant analysis. In conclusion, our data identified novel roles for CD44 in hemopoiesis: regulation of the HSC and progenitor pool, migration of fetal hemopoietic cells to different microenvironments, homing and spatial distribution of adult HSC, and hemopoietic reconstitution. In hematological malignancies, quiescent leukemic stem cells are responsible for persistence of minimal residual disease and relapse. Emerging evidence points to the involvement of the bone marrow microenvironment in survival and systemic retention of leukemic stem/progenitor cells. Integrins, particularly α4β1, which controls hematopoietic stem cell trafficking, were shown to be required for leukemic stem cells lodging to the bone marrow niche, and were shown to be crucial for the persistence of minimal residual disease. The molecular mechanism governing these processes is not known. We have just recently obtained evidence that newly identified α4 integrin-Abelson interactor 1 (Abi1) signaling cross-talk is involved in acquired drug resistance in Bcr-Abl positive leukemic cells. Comparison of mRNA levels of Abi1 and α4 integrin in Bcr-Abl positive CD34 + progenitor cells isolated from blood or bone marrow of chronic myelogenous leukemia (CML) patients at diagnosis and at relapse revealed decrease in mRNA levels of Abi1 and increase in mRNA levels of α4 integrin in relapsing, non This work was supported by the National Center for Research Resources (VF) (5P20RR018757-10) and the National Institute of General Medical Sciences (VF) (8 P20 GM103414-10). To learn more about these agents, a review was conducted to identify the specific types and mechanisms underlying the lymphohematopoietic cancers induced by chemical agents and radiation in humans, with a primary emphasis on acute myeloid leukemia. A number of mechanisms were identified that play key roles in the formation of lymphohematopoietic cancers. Immunomodulating agents are primarily associated with the induction of lymphomas, whereas mutagenicity and genotoxicity play important roles in the chemically related leukemias. Major classes of leukemia-inducing agents include ionizing radiation, chemotherapeutic alkylating agents, and topoisomerase II inhibitors, as well as a number of occupational and environmental agents. These leukemia-inducing agents have different potencies and risks, which appear to be influenced by the specific mechanisms involved in leukemogenesis. This presentation will briefly review the major classes of leukemia-and lymphoma-inducing agents and discuss how mechanistic information on human leukemia-inducing agents may be used to better inform the potential risks from exposure to environmental chemicals. Identifying specific cancer-causing agents with their associated mechanisms, and using this information to inform key steps in risk assessment, is ongoing challenge for researchers and risk assessors. Moreover, osteoblastic differentiation seems to be dysregulated. Furthermore, we showed that in steadystate hematopoiesis the content of (Lin -cKit + Sca1 + Cd34 -Cd150 + ) HSC is increased in Wnt5a +/-mice. Since abnormalities in the niche may contribute to leukemogenesis, we studied whether Wnt5a in the niche affects the development in a model of Bcr-Abl + leukemia. In Wild-Type animals, Bcr-Abl transduced hematopoietic cells induced leukemia with a latency time (50%-survival) of 70 days. In contrast to that, in Wnt5a-heterozygous mice, the latency time was shortened to 40 days, demonstrating that extrinsic Wnt5a level affect the onset of leukemia. These results also confirm a role of Wnt5a as tumor suppressor. Interestingly, more leukemic Bcr-Abl + LSK cells were found if the leukemia developed in the Wnt5+/-environment, suggesting an increase self-renewal of leukemic stem cells. Enhanced leukemogenesis was associated with increased canonical Wnt-signaling in leukemic cells with a concomitant decrease in noncanonical signaling. Our study shows the balance between Wnt5a-modulated canonical and noncanonical Wnt signaling pathways regulates both hematopoiesis and leukemogenesis. The contribution of the bone marrow (BM) microenvironment in myelodysplastic syndrome (MDS) is controversially discussed. Intertwined activity of multipotent mesenchymal stromal cells (MSC) and monocyte/osteoclasts (MON-OC) regulate the hematopoietic niche, and their functionality in different MDS disease stages has not been systematically investigated. We have studied the properties of primary cells from patients with lower-risk MDS with and without del(5q) or higher-risk MDS. Compared to agematched healthy controls, MDS-MSC showed impaired clonal potential and growth with distinct degrees of differentiation defects, particular expression of adhesion and cell surface molecules important for intercellular communication, and altered secretion of niche cytokines, among them lower stromal derived factor 1α level and Kit-l expression. Healthy CD34+ hematopoietic stem and progenitor cells (HSPC) migrated less towards MDS-MSC culture supernatants, produced reduced numbers of cobblestone area forming-cells and fewer colony forming units compared to control when cultured with disease stroma, and interestingly presented increased proliferation with high risk MDS-MSC coculture. High risk stroma provoked increased apoptosis on leukemic cells compared to low risk MDS and healthy controls. We could demonstrate that BM MON-OC progenitor's numbers are reduced and the ability of CD14+ cells to generate terminally differentiated bone reabsorbing osteoclasts is impaired. Interestingly, osteogenic differentiated MDS-MSC are not able to provoke an increase in osteoclast numbers with healthy CD14+ cells, while MDS progenitors in presence of MDS-stroma show higher osteoclast differentiation. Our analyses support the notion of involvement of the bone marrow microenvironment in the pathophysiology of MDS thus representing a potential target for therapeutic approaches. Interactions with the hematopoietic niche in the bone marrow (BM) microenvironment are essential for hematopoietic stem cell (HSC) self-renewal. In addition, this niche is considered to serve as a sanctuary site for leukemic stem cells during chemotherapy, and contributes to disease relapse. Although many advances have been made in understanding how the niche regulates HSC self-renewal and confers therapy resistance, most of this knowledge is based on genetically engineered murine models. Given the need for models that more closely resemble the human niche, we developed a humanized model in which a scaffold seeded with human BM stromal cells generates a bone microenvironment. Inoculation of these mice with human CD34+ -progenitor cells resulted in homing to the human bone environment and the generation of hematopoietic cells of distinct lineages and the engraftment of CD34+ cells themselves. The functionality of these humanized niches was further investigated with primary samples obtained from patients diagnosed with MDS, AML, T-ALL and MM cells, malignancies that are highly dependent on the BM microenvironment for survival and growth. In addition, by gene-marking MM and T-ALL cells with luciferase and using bioluminescent imaging, we were able to follow tumor outgrowth in time. Importantly, in this model, the response of primary MM cells to established anti-MM agents correlates with clinical responses of the respective patients. Hence, our model allows us to investigate essential interactions within the human BM microenvironment for the development of normal and malignant hematopoiesis and thus for therapy development.
THE ROLE OF CD44 IN

BLOOD VESSELS ARE SANCTUARY SITES FOR ACUTE MYELOID
LYMPHOHEMATOPOIETIC CANCERS INDUCED BY THERAPEUTIC AND ENVIRONMENTAL AGENTS AND THEIR IMPLICATIONS FOR RISK EVALUATION
DECREASE OF WNT5A EXPRESSION IN THE NICHE AFFECTS BOTH MESENCHYMAL STROMAL CELLS AND THE BEHAVIOR OF HSC IN BCR-ABL
FUNCTIONAL ANALYSIS OF THE BONE MARROW MICROENVIRONMENT
RECONSTRUCTING THE HUMAN HEMATOPOIETIC NICHE: OPPORTUNITIES FOR STUDYING NORMAL AND MALIGNANT HEMATOPOIESIS
INVESTIGATION INTO THE CROSS TALK BETWEEN AML CELLS AND THE BONE MARROW MICROENVIRONMENT
Ashley Hamilton, PhD, Katie Foster, PhD, Dominique Bonnet, PhD Cancer Research UK, London Research Institute, London, United Kingdom
The cell fate of the hematopoietic stem cell (HSC) to either self-renew or differentiate is controlled by a complex interplay between cell-intrinsic and -extrinsic regulatory signals generated by the surrounding bone marrow microenvironment called the HSC niche. A balance exists within the "cross talk" between HSCs and the niche, which allows HSC dormancy, activation and differentiation. Any alterations of this balance may lead to uncontrolled cellular proliferation and ultimately to the promotion of leukemias. However, it remains to be determined exactly how the hematopoietic microenvironment contributes to the deregulation of normal hematopoiesis and/or promotes the maintenance of leukemia cells as a "leukemic niche". To investigate this, we have now performed micro-array analysis of MS5 stromal cells that were co-cultured with a panel of leukemic cell lines and acute myeloid leukemia (AML) patient samples. The most significantly upregulated pathways as compared to MS5 cells cultured alone involved cytoskeleton remodeling, cell cycle, cell adhesion and development through cytokine signaling. Since a number of effectors of the TGF-beta signaling pathway were upregulated in the stroma co-cultured with leukemic cells, we next investigated inhibition of this pathway using a specific inhibitor of TGF-beta receptor kinase, SB-431542. Treatment with the inhibitor significantly increased the levels of apoptosis in the AML cells co-cultured on stromal cells, whilst having no effect on normal cells, and also reduced the level of AML cell engraftment on treatment in vivo. These data highlight the potential for the development of therapies directed at modifying the bone marrow microenvironment. Hematological malignancies such as leukemia and multiple myeloma proliferate in the bone marrow (BM) to the detriment of the normal hematopoietic cells. Therefore, it is suspected that these malignant cells use similar mechanisms as the normal hematopoietic stem cells (HSCs) to localize in the BM and propagate disease. We are investigating the role of the HSC niche in multiple myeloma (MM) by using the 5T mouse model of MM. We hypothesize that the interaction of the chemokine stromal cell-derived factor -1 alpha (SDF-1α) with its receptor CXCR4 plays a major role in the homing and retention of MM cells to the BM. Following CXCR4 knockdown in 5TGM1 cells in vitro, we demonstrated a lower calcium flux in response to SDF-1a. However, while there was no effect on the cell cycle status, the growth rate appeared to be increased in the knockdown cells. In vivo analysis of the CXCR4 knockdown 5TGM1 cells suggested that there was a 25% reduction in the number of cells homing to the BM. Currently, we are investigating the impact of reduced CXCR4 expression on lodgment of MM in the BM microenvironment and the effect on the pathophysiology of the disease. We are also examining components of the BM microenvironment such as mesenchymal stem cells and BM stromal cells in the 5T mouse model and WT C57Bl/6 mice to elucidate the mechanisms that render the BM microenvironment in the 5T model conducive to MM development. Myelodysplastic syndromes (MDS) comprise a heterogeneous grouping of diseases that differ in diagnostic criteria, treatment, prognosis and likely etiology. Recent advances in experimental and clinical hematology have led to the identification of subsets of MDS patients presenting with clear evidence of immunologic dysregulation. Further, there are a variety of conditions that can result in significant dysplastic features observed in the bone marrow that defy current classification schemes. The success of immunosuppressive therapy (IST) in 'MDS' cases that arise concomitant with various autoimmune disorders provide very clear evidence that immune dysregulation can result in bone marrow dysplasia. Other, less well-described causes include reports of myelodysplastic-like syndromes associated with pregnancy and certain drugs used in the treatment of tuberculosis. There is also clear immune cell involvement in patients with MDS subsequent to chronic benzene exposure. Many of these cases lack evidence of clonal cytogenetic abnormalities, which implies a non-genotoxic mechanism. Collectively, multiple independent lines of evidence support that altered immune response plays a prominent pathogenic role in some forms of bone marrow dysplasia. Here we describe the clinical features of patients who develop bone marrow dysplasia characterized by immune-mediated alterations. Using these disparate causes of bone marrow dysplasia, we also characterize the possible pathogenic mechanisms that may underlie the resulting disorders. We believe this characterization may be useful for future investigations. Lastly, we suggest an alternative nosologic system to highlight the unique features and etiology of these dysplastic disorders. Apoptosis defects are characteristic for chronic lymphocytic leukemia (CLL). CLL cells harbor an excess of anti-apoptotic proteins. Remarkably, this de-regulation of anti-apoptotic proteins is not sufficient to maintain long-term survival of CLL cells. Bone marrow stromal cells (BMSCs) play an important role for microenvironment mediated survival of CLL cells. Importantly, interactions between CLL cells and BMSCs not only protect leukemic B-cells from spontaneous, but also from drug-induced apoptosis. Here we describe that CLL cells activate the expression of proteinkinase C-β in BMSCs. Furthermore, following induction of PKC-β, BMSCs activate NF-кB. Interference with the NF-кB activation in BMSCs suspended the prosurvival effects on CLL cells, similar to PKC-β deficient stromal cells. Analysis of gene expression profiles of stromal cells either proficient or deficient for PKC-β in response to contact with CLL cells revealed gene expression clusters related to extracellular matrix protein interactions. Specifically, the matrix-metalloproteinases MMP13 is significantly upregulated in stromal cells upon CLL contact. Blocking MMP13 using molecular inhibitors demonstrate that the prosurvival effect of BMSCs on CLL cells is abolished. To demonstrate that the PKC-β pathway is also important in vivo, Tcl1-CLL was transplanted into syngeneic PKC-β knock-out and wild-type mice. Notably, all PKC-β wild-type mice died of a CLL-like disease, whereas PKC-β knock-out animals were entirely resistant to CLL transplants. Conclusively, we describe a novel survival signaling pathway activated by monoclonal B-cells in BMSCs. Interference with the PKC-β-NF-кB pathway activated in the leukemia microenvironment may offer new therapeutic options to fully eradicate malignant B-cells from bone marrow niches. Tetraspanins have the unique ability to interact with multiple cell surface molecules and cytosolic signaling components to regulate multiple cellular processes including cellular adhesion, signal transduction, cancer progression, and exosome trafficking. Our work has implicated a role for the specific tetraspanin, CD82, in cellular communication between hematopoietic stem cells and their niche, more specifically in the processes of homing, engraftment and adhesion. We found that knockdown of CD82 (CD82KD) in Kg1a cells (CD34+ hematopoietic progenitor-like cell line) significantly decreases adhesion to osteoblastic cells. Adhesion to recombinant N-cadherin recapitulates the adhesion to osteoblastic cells suggesting that N-cadherin, at least in part, mediates adhesion between these cells. We observed that CD82KD results in the loss of N-cadherin expression, consequently decreasing β-catenin protein stabilization. The disruption of the Wnt/β-catenin signaling pathway results in an increased susceptibility to cellular stress resulting in apoptosis. Co-culture of osteoblastic cells with hypoxic CD82KD cells or their purified exosomes attenuates the VEGF release by osteoblastic cells. In contrast, CD82 overexpression diminishes stress-induced apoptosis and enhances VEGF release from osteoblasts. Therefore, expression of CD82 on hematopoietic progenitor-like cells enhances adhesion, protects against apoptosis, and increases VEGF production to and by the stem cell niche. We will also discuss our recent findings evaluating the hematopoietic stem cell population within the CD82 knockout mice. These data present a critical role for the expression of CD82 in the maintenance of hematopoietic stem cells in the niche microenvironment. Poor outcomes in patients with acute myeloid leukemia (AML) are related to the high proportion of patients with chemo-refractory disease or relapse after an initial response due the development of resistance. This treatment failure is frequently due to the persistence of leukemic stem/progenitor cells that are inherently resistant to classical chemotherapeutic agents, in part because of an increased efflux of these agents via ABC transporter proteins. The main approach to overcome the transporter effect has involved the co-administration of competitive inhibitors of these transporters. However, the large number of failed clinical trials involving such inhibitors has demonstrated the need to adopt different strategies. Here, we propose the exploration of an approach in treatment of AML that utilizes molecules with either a higher binding affinity than paclitaxel or covalent binding to their targets. We have evaluated in vitro toxicity of a series of fifteen synthetic paclitaxel analogues (chitaxes), with high binding affinities, as well as the marine molecule zampanolide with covalent binding ability and seven of its analogues. Drug sensitivity was determined on a panel of AML cell lines sensitive and resistant to paclitaxel. Most molecules were active with EC50 values in the sub-nanomolar range. We have performed studies using chitaxes and zampinolides in combination with daunorubicin and cytarabine and have characterized the kinetics of apoptosis induction and cell cycle arrest. We are investigating the effect of these molecules on normal human hematopoietic progenitors and stem cells by colony forming unit assays and cobblestone area-forming assay, respectively. The relationship between cigarette smoking and an increased risk of AML has been well documented. While the overall risk is modest, the number of smokers is very large. As a result, cigarette smoking is currently considered the single most important cause of AML in the US. It is assumed that the leukemogenic activity of cigarette smoke is related to the benzene or benzene metabolite content. It is also well documented that AML is not a single disease, but comprised of several different subtypes (depending upon the classification system utilized). One is the M3 subtype (per the FAB) or acute promyelocytic leukemia (APL) that is distinctly different from other subtypes of AML in terms of its diagnostic criteria, treatment, cytogenetic abnormalities and prognosis. While many studies demonstrate the relationship between cigarette smoking and AML, there have only been six studies that have formally evaluated the risk between cigarette smoking and various subtypes of AML. All six of these studies reported elevations in most subtypes of AML but not APL or AML with t(15;17). Here we conducted a meta-analysis of this data set and determined that the overall risk for APL among smokers was statistically significantly suppressed [summary OR = 0.5, 95% CI 0.3-0.8], with good homogeneity between the studies. In contrast, the summary OR for the M2 subtype of AML was significantly elevated [OR = 2.03, 95% CI = 1.41-2.90]. These data indicate that cigarette smoking (or benzene exposure) is not likely a causative factor in the development of APL.
EVIDENCE FOR AN IMMUNOLOGIC ROLE IN THE PATHOGENESIS OF SOME FORMS OF
PROTEIN KINASE C-β DEPENDENT ACTIVATION OF NF-кB IN STROMAL CELLS IS INDISPENSABLE FOR THE SURVIVAL OF CRONIC LYMPHOCYTIC LEUKEMIA B CELLS IN VIVO
Gloria Lutzny
EXPRESSION OF CD82 PROMOTES HEMATOPOIETIC STEM CELL SURVIVAL AND
INVESTIGATION OF ANTITUMOR EFFECT OF THE TUBULIN-BINDING AGENTS CHITAX AND ZAMPANOLIDE IN ACUTE MYELOID LEUKEMIA
A META-ANALYSIS OF AML SUBTYPES REPORTED IN CIGARETTE SMOKERS
PREVENTION OF IMATINIB-INDUCED INCREASES IN CXCR4 LEVELS AND CML CELL MIGRATION BY INHIBITORS OF NRH:QUINONE OXIDOREDUCTASE 2 (NQO2) -A POTENTIAL MECHANISM TO PREVENT CXCR4-MEDIATED IMATINIB RESISTANCE IN CML
David Ross, PhD, Kun-Che Chang, MS, Maura Gasparetto, MD, Manoj Pilai, MD, Clayton Smith, MD, David Siegel, PhD University of Colorado Anschutz Medical Campus, Aurora, CO.
A novel mechanism of resistance to imatinib and other tyrosine kinase inhibitors (TKI's) is the migration of leukemia cells to the bone marrow niche mediated by CXCR4/SDF-1. The niche provides a favorable environment for CML stem cell survival. NQO2 is a major non-kinase target of imatinib and we explored a potential role of NQO2 in modulating CXCR4 expression and migration in CML cells. In a transwell system, K562 cells were co-cultured with SDF-1 producing Hs27a bone marrow epithelial cells and addition of imatinib was found to cause a significant increase in CXCR4 levels on the surface of K562 cells. However, addition of MD365, a potent suicide inhibitor of NQO2, together with imatinib blocked the increase in CXCR4. To confirm this observation, we developed K562 cells with stable knockdown of NQO2 (96% knockdown). Imatinib increased levels of surface CXCR4 in NQO2-competent K562 cells but not in the NQO2-knockdown clone. We next examined CML cell migration in the same transwell system and imatinib induced K562 cell migration into Hs27a conditioned medium but migration was prevented by either inhibition of NQO2 with MD365 or stable knockdown of NQO2. Preliminary data also showed a similar inhibition of imatinib-induced CXCR4 increases in co-cultured primary CML cells using the NQO2 inhibitor MD365. These data demonstrate that either NQO2 inhibition or knockdown prevented imatinib-induced increases in surface CXCR4 levels in CML cells and CML cell migration. The use of NQO2 inhibitors provides a potential mechanism whereby CXCR4 mediated imatinib resistance can be prevented. Most benzene risk assessments and focused mechanistic work assumes that acute myeloid leukemia (AML) is the key effect from benzene exposure. We recently reported a relationship between myelodysplastic syndrome (MDS) and benzene exposure among a pooled population of petroleum distribution workers (Schnatter, et al., 2012) . This relationship was strongest for cumulative benzene exposure (Odds Ratio = 4.3 for >2.93 ppm-years; p=0.03) and a peak exposure metric (Odds Ratio = 2.5; p=0.05), and indicated a relationship with MDS at levels lower than previously reported. Conversely, the study did not show compelling evidence that AML was related to benzene exposure at these relatively low benzene levels. There are two scenarios that are consistent with this study's findings and the previous literature on MDS and AML. The first scenario involves MDS progression to AML. This hypothesis would assume MDS is a key event on the way to benzene-induced AML. The second scenario hypothesizes that AML and MDS are independent effects from benzene exposure. Since MDS was found at lower exposures in this population and AML was not, it is possible that MDS is the more sensitive indicator of benzene exposure. We will discuss empirical data which both supports and argues against each of these scenarios. Each scenario has different implications for the mechanistic basis of benzene-induced myeloid neoplasia as well as future benzene risk assessment. The interactions between hematopoietic stem cells (HSC) or malignant leukemic cells and their niche need to be studied at the single cell level. For this purpose, live animal cell tracking with confocal or multiphoton imaging has proven very useful, but taken alone it does not allow investigators to control the spatial location of the cells of interest. A system having the ability to directly implant single cells in spatially defined niches would enable us to acquire a better understanding of the relationship between cells and their niche and to better define this microenvironment.
MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA AND BENZENE EXPOSURE: IMPLICATIONS OF RECENT FINDINGS
HEMATOPOIETIC STEM CELLS (HSC) OF ARYL HYDROCARBON RECEPTOR KNOCKOUT MICE (AhR-KO) HAVE ABNORMAL ROS, у-H2AX, p16 LEVELS AND GENE EXPRESSION THAT MAY BE ASSOCIATED WITH EARLY AGING AND HEMATOPOIETIC NEOPLASMS
We have developed an all-optical system allowing the delivery of single cells in the calvarium bone marrow of live mice. Laser ablation is used to drill a microchannel to reach a specific location in the bone marrow. A single cell is then brought close to the channel with a micropipette, and released into an optical tweezer. The trapped cell can thus be positioned in the desired location. All manipulations are performed under real-time optical microscopy guidance. The platform was successfully used to deliver HSC and leukemic (Nalm6) cells. The later remained in the calvarium bone marrow and were able to proliferate. Acute leukemias account for ~30% of all childhood malignancy across the western world. The majority of these cases (~80% ALL and ~60% AML) have rearrangements involving the MLL gene. MLL breakpoint sequences associated with infant acute leukemia are similar to those in secondary AML following exposure to the topoisomerase II (topoII) poison etoposide. This indicates that exposure during pregnancy to biochemically similar compounds may promote infant acute leukemia. Some studies have shown epidemiological links between some dietary and environmental topoII inhibitors and increased incidence of MLL-rearranged infant leukemias. Our goal was to create a model system for screening these compounds to determine their potential to directly promote an MLL translocation. Thus, we developed reporter stem cell lines containing two transgene constructs: (1) the MLL bcr fragment containing a genetically-engineered GFP 5' exon; and (2) the AF9 bcr fragment containing a geneticallyengineered GFP 3' exon. A translocation between the bcrs reconstitutes full-length GFP transcript resulting in quantifiable green fluorescence. Cells at three stages of differentiation were treated with etoposide or one of five compounds which have been linked to increased incidence of infant leukemia. Our results show that bioflavonoids and topoII inhibitors genistein and quercetin are potent promoters of MLL-AF9 translocations in stem cells and hematopoietic stem cells indicating they may directly initiate leukemia early in development. These compounds are widely available as dietary supplements and are perceived to prevent cardiovascular disease, inflammation, and cancer; however, this model system demonstrates that they have the potential to promote translocations analogous to those observed in infant leukemias.
IDENTIFICATION OF DIETARY AND ENVIRONMENTAL COMPOUNDS THAT PROMOTE
MARROW MICROENVIRONMENTAL EFFECTS OF THE VASCULAR DISRUPTING AGENT, ASA404 (DMXAA) IN PRECLINICAL HUMAN LEUKEMIA MODELS
Scott Portwood, MS, Deepika Lal, MS, Christopher Schaefer, MS, Odochi Uwazurike, BS, Joseph A. Spernyak, PhD, Mukund Seshadri, PhD, Eunice S. Wang, MD Roswell Park Cancer Institute, Buffalo, New York, USA ASA404 (5,6-dimethylxanthenone-4-acetic acid, DMXAA) is known to be a potent anti-inflammatory and vascular disrupting agent in solid tumors but has not previously been investigated in hematological malignancies. In local leukemia xenografts, a single administration of ASA404 (25 mg/kg) markedly enhanced tumor vascular permeability, as determined by magnetic resonance imaging at 4 hours, followed by vascular disruption and central necrosis at 24 hours. In systemic leukemia xenografts, a single dose of ASA404 enhanced marrow vascular permeability and induced several-fold elevations in host chemokine levels in circulating plasma as well as bone marrow, liver, and spleen cells. Continuous ASA404 treatment (20 mg/kg twice weekly) for up to three weeks in established systemic leukemia xenografts in mice resulted in marked marrow disruption and inhibition of tumor growth. Prolonged in vivo ASA404 treatment also led to higher baseline host TNF-levels and increased numbers of macrophages within the leukemic marrow microenvironment. Administration of ASA404 24 hours prior to human acute myeloid leukemia cell inoculation in immunodeficient mice and continued after inoculation resulted in the optimal anti-tumor effects and significantly prolonged overall survival. Combination treatment with ASA404 and doxorubicin further improved therapeutic responses over single agent therapy. Quantification of doxorubicin levels within leukemia disease sites (specifically local tumor xenografts and leukemic marrow samples) revealed several-fold higher tissue drug levels following ASA404 versus vehicle therapy consistent with ASA404-mediated improvements in tumor drug delivery. Our results demonstrate that ASA404 exerts anti-tumor activity in human leukemia xenograft models via myriad unique effects on the leukemic marrow microenvironment. Using various coculture models, we investigated whether DTCs can change the bone marrow microenvironment by modulating MSC function with a special emphasis on their chemoattractive activity towards hematopoietic stem and progenitor cells (HSPCs). Human bone marrow derived MSCs were cocultured with MCF-7, MDA-MB231 breast carcinoma or MCF-10A non-malignant breast epithelial cells or their conditioned medium. Both tumor cell lines caused an inhibited SDF-1 promoter activity in MSCs, whereby MCF-7 medium decreased it to 77% and MDA-MB231 to 47%. Moreover, the SDF-1 mRNA levels were reduced to about 50%. Conditioned medium of the tumor cell lines decreased the SDF-1 protein secretion significantly to 47%, 37% and 33% after 1, 3 and 5 days, respectively. At least, in part, this effect was mediated by an impaired transcriptional activity of SP1. As a functional consequence of lower SDF-1 levels, we observed decreased transwell migration potential of CD34+ HSPCs to MSC/tumor cell cocultures or conditioned medium. Further relevant findings were an enhanced TGFα1 expression and changed expression pattern of the gap-junction molecule connexion-43 (Gja1) suggesting an interference with stromal cell-cell interactions by DTCs. In conclusion, we propose an additional mechanism by which tumor cells affect the niche environment of HSPCs and therefore negatively impact on hematopoiesis even in early tumor stages.
BREAST CARCINOMA CELLS MODULATE THE BONE MARROW NICHE BY INTERFERING
MICROSOMAL EPOXIDE HYDROLASE (EPHX1) POLYMORPHISMS ARE ASSOCIATED WITH ABERRANT PROMOTER METHYLATION OF ERCC3 AND HEMATOTOXICITY IN BENZENE-EXPOSED WORKERS
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